ENHANCED SPECIALTY GUIDELINE MANAGEMENT

HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human])

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication
Routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in adolescent and adult patients

All other indications are considered experimental/investigational and are not a covered benefit.

II. DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review:

A. C4 levels and C1 inhibitor functional and antigenic protein levels
B. F12, angiopoietin-1 or plasminogen gene mutation testing, if applicable
C. Chart notes confirming family history of angioedema, if applicable

III. CRITERIA FOR APPROVAL

Authorization of 12 months may be granted for prevention of hereditary angioedema attacks when Haegarda will not be used in combination with Cinryze or Takhzyro and either of the following criteria is met:

A. Member has C1 inhibitor deficiency or dysfunction as confirmed by laboratory testing.
   1. C1 inhibitor (C1-INH) antigenic level below the lower limit of normal as defined by the laboratory performing the test; or
   2. Normal C1-INH antigenic level and a low C1-INH functional level (functional C1-INH less than 50% or C1-INH functional level below the lower limit of normal as defined by the laboratory performing the test)
B. Member has normal C1 inhibitor as confirmed by laboratory testing and meets one of the following criteria:
   1. Member has an F12, angiopoietin-1, or plasminogen gene mutation as confirmed by genetic testing, or
   2. Member has a documented family history of angioedema and the angioedema was refractory to a trial of high-dose antihistamine (e.g., cetirizine) for at least one month.

IV. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continuation of therapy when all of the following criteria are met:

A. Member meets the criteria for initial approval.
B. Member has experienced reduction in frequency, severity, and/or duration of attacks since starting treatment.
V. REFERENCES